Drug interactions and pharmacokinetics: latest news

Drug interactions and pharmacokinetics resources

Drug interactions and pharmacokinetics features

Drug interactions and pharmacokinetics news from aidsmap

More news

Drug interactions and pharmacokinetics news selected from other sources

  • Taking Birth Control With HIV Treatment or PrEP Is Largely OK

    Women taking various forms of hormonal contraceptives can likely combine them safely with antiretrovirals (ARVs), whether as HIV treatment or in the form of Truvada (tenofovir disoproxil fumarate/emtricitabine) as pre-exposure prophylaxis (PrEP) against the virus. The one ARV that may be problematic to combine with such forms of birth control is Sustiva (efavirenz), which is included in Atripla (efavirenz/tenofovir disoproxil fumarate/emtricitabine).

    30 May 2017 | Poz
  • Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

    Several anecdotal reports of mouth ulcers have recently been reported in people switching to generic abacavir in the UK. This should highlight awareness of the potential of likely-rare new side effects, even when both formulations have been approved as bioequivalent.

    23 May 2017 | HIV i-Base
  • New nano approach could cut dose of leading HIV treatment in half

    Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.

    21 February 2017 | University of Liverpool press release
  • Gates Foundation to Invest Up to $140 Million in HIV Prevention Device

    The tiny implantable drug pump is being developed by Intarcia Therapeutics Inc. It can hold six or 12 months’ supply of medicine and is designed to deliver microdoses continuously to patients, ensuring they stay on the treatment.

    30 December 2016 | Wall Street Journal
  • What's at Stake in Trump's America? HIV Community Leaders Share Their Opinions

    By Election Day Nov. 8, after an eventful primary season and a noxious election cycle, it seemed that most HIV advocates were ready to get to work with a soon-to-be President-elect Hillary Clinton's soon-to-be administration, to continue the pioneering work activists forged under President Obama in addressing HIV in the U.S. Then the unthinkable happened. In the wee hours of Nov. 9, Donald J. Trump was declared the president-elect of the United States.

    21 November 2016 | The Body
  • Evidence that “on-demand” PrEP taken before and after sex can prevent HIV

    How many doses of Truvada-based PrEP (pre-exposure prophylaxis) are needed to provide adequate protection against HIV? Might it be possible to take PrEP only before and after sex—instead of every day?

    12 September 2016 | BETA blog
  • University HIV smartphone app receives international award

    A smartphone application developed by the University of Liverpool to help healthcare professionals to safely prescribe medications for HIV patients has won an international award.

    01 September 2016 | University of Liverpool press release
  • Women need more of the HIV drug Truvada than men to prevent infection

    Women need daily doses of the antiviral medication Truvada to prevent HIV infection while men only need two doses per week due to the way the drug accumulates in different body tissues, according to a new study from pharmacy researchers the University of North Carolina at Chapel Hill.

    04 March 2016 | Eurekalert Medicine & Health
  • Study: HIV can hide and grow in 'sanctuaries' in body after it's undetectable in blood

    The latest study appears to show a different type of "sanctuary," as the researchers called it, harboring cells with low levels of HIV replication that move into the blood. This suggests that virus growth could occur in a place where drug concentrations are very low.

    28 January 2016 | Washington Post
  • Many patients on new HCV medications at risk of drug-drug interactions

    Many patients taking direct acting antivirals (DAA) to treat hepatitis C virus (HCV) are at risk of clinically significant drug-drug interactions (DDIs), new research shows.

    23 December 2015 | Medscape (requires free registration)
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.